Strand Life Sciences Plans CancerSpot Expansion to US, Southeast Asia, Middle East

The company is pursuing US Food and Drug Administration (FDA) approval for the test, which screens for 14 cancers, and expects the regulatory process to reach a key milestone around February-March next year.

The US would be the company’s next export market once approval comes through, according to a company representative. While regulatory requirements vary across markets, Strand intends to pursue approvals wherever they are required.

Dr Ramesh Hariharan, chief executive officer of Strand Life Sciences, said,

ArthNow market news brief
Photo: arthnow.com

“In most regions of the world, one doesn’t (require regulatory approval to operate). Our aspiration is global.”

Hariharan also said that such clearances help build confidence among clinicians and other stakeholders.

The test is intended to complement, rather than replace, established screening methods such as mammography and colonoscopy, and covers several cancer types for which routine screening options are limited or unavailable.

A four-year study conducted across 43 hospitals in India involved around 1,400 participants, including about 950 people with cancer and 450 healthy individuals. The study reported that the test detected 72 per cent of cancers, including around 65-70 per cent at early stages, while recording a false-positive rate of 1.4 per cent in an independent set of participants.

Because positive screening results require follow-up investigations and clinical care, Strand is in discussions with hospitals and academic institutions on collaborations, including larger clinical studies, while working to build awareness among doctors and patients.

Strand Life Sciences was founded in October 2000 by Professors Vijay Chandru, Ramesh Hariharan, Swami Manohar, and V. Vinay, and is headquartered in Bangalore. In 2021, Reliance Industries’ subsidiary Reliance Strategic Business Ventures acquired a controlling stake in the company.

Strand is credited with building India’s first CAP-accredited genomic lab and developing the country’s first methylation-based early cancer detection test. The company carries out 40,000-50,000 tests annually and operates a network of about 2,500 clinics and hospitals in India and 10 countries across Asia, Southeast Asia, and the Middle East.

Domestically, Strand is looking to make the test more affordable in India. It is currently priced at up to ₹25,000 for patients, with the company targeting a price of less than ₹10,000 over the next few years.

Reducing costs will depend on improvements in sequencing technology, procurement and laboratory processes, alongside higher volumes. Strand said that its sequencing equipment is shared with wider genomics testing operations, whereas sample collection, assay development and research account for a large portion of the costs.

Photo of author

Newsroom

Newsroom at Archyde.

Endrick Faces an Uncertain Future at Real Madrid